Physician profile
Adefunke Adedipe
NPI 1114313590
$289.65
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $202 · 2020: $34.70 · 2022: $52.75.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $81.69 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.93 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $31.70 | 2020-2022 | |
| Amarin Pharma, INC. | $25.72 | 2019 | |
| Sanofi-Aventis U.S. LLC | $22.71 | 2019 | |
| Amgen INC. | $18.22 | 2019 | |
| Insulet Corporation | $14.71 | 2019 | |
| Valeritas, INC. | $14.00 | 2019 | |
| Pfizer INC. | $12.90 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.75 | 2019 | |
| Merck Sharp & Dohme LLC | $11.32 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adefunke Adedipe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.